SEC Company Response from Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Sep 15, 2014
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: Sept. 15, 2014 · CIK: 0001607678 · Accession: 0001193125-14-341742
AI Filing Summary & Sentiment
File numbers found in text: 333-197182
Letter
Underwriter Acceleration request
September 15, 2014
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Johnny Gharib, Esq.
Re: Viking Therapeutics, Inc.
Registration Statement on Form S-1
Registration No. 333-197182
Acceleration Request
Requested Date:
Wednesday, September 17, 2014
Requested Time:
4:00 p.m., Eastern Daylight Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Oppenheimer & Co. Inc. and Roth Capital Partners, LLC, as representatives of the several underwriters, hereby join Viking Therapeutics, Inc. in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-197182) (the “Registration Statement”) to become effective on Wednesday, September 17, 2014 at 4:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 1,547 copies of the Preliminary Prospectus dated September 8, 2014 through the date hereof, to underwriters, dealers, institutions and others.
We will, and we have been informed by the participating underwriters that they will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
Very truly yours,
OPPENHEIMER & CO. INC.
Show Raw Text
CORRESP 1 filename1.htm Underwriter Acceleration request September 15, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Johnny Gharib, Esq. Re: Viking Therapeutics, Inc. Registration Statement on Form S-1 Registration No. 333-197182 Acceleration Request Requested Date: Wednesday, September 17, 2014 Requested Time: 4:00 p.m., Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Oppenheimer & Co. Inc. and Roth Capital Partners, LLC, as representatives of the several underwriters, hereby join Viking Therapeutics, Inc. in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-197182) (the “Registration Statement”) to become effective on Wednesday, September 17, 2014 at 4:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter. Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 1,547 copies of the Preliminary Prospectus dated September 8, 2014 through the date hereof, to underwriters, dealers, institutions and others. We will, and we have been informed by the participating underwriters that they will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable. Very truly yours, OPPENHEIMER & CO. INC. By: /s/ Douglas Cameron Name: Douglas Cameron Title: Head of Equity Capital Markets ROTH CAPITAL PARTNERS, LLC By: /s/ Aaron M. Gurewitz Name: Aaron M. Gurewitz Title: Head of Equity Capital Markets cc: Michael D. Maline, Esq., Goodwin Procter LLP Jeffrey T. Hartlin, Esq., Paul Hastings LLP